VintaBio’s development and manufacturing team has over a century of experience in the cell and gene therapy space and its members have played key roles in the development of the most advanced therapies on the market today. Located in the historic Navy Yards of Philadelphia – the epicenter of cell and gene therapy innovation – VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, a vital and currently underserved area of CGT development. The company was founded by Junwei Sun and Dr. Shangzhen Zhou, who led development of the AAV vectors behind the first two FDA-approved gene therapies, as well as the lentiviral vector for the first FDA-approved cell therapy. VintaBio has raised $64 million in venture funding, which has been used to develop a brand new 22,500 square foot facility in Philadelphia created specifically to facilitate efficient cell and gene therapy manufacturing.
Company Details
- Employees
- 31
- Founded
- -
- Address
- 4050 S 26th St, Philadelphia,pennsylvania 19112,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vintabio.com
- Keywords
- Gene Therapy and Viral Vectors.
- HQ
- Philadelphia, Pennsylvania
Vintabio Questions
Vintabio's website is http://www.vintabio.com
Vintabio's LinkedIn profile is https://www.linkedin.com/company/vintabio
Vintabio has
31 employees.
View email and phone details for 31
employees at Vintabio.
Vintabio's industry is
Biotechnology Research
Vintabio's top competitors are
Interius Biotherapeutics,
Gsk,
Iovance Biotherapeutics, Inc.,
Sk Pharmteco,
Spark Therapeutics, Inc.,
Vector Biomed, Inc.,
Adaptimmune,
Cabaletta Bio,
Verismo Therapeutics,
Legend Biotech.
Vintabio's categories are Biotechnology Research
Vintabio's founding year is 2020
